Novel LIPA-Targeted Therapy for Treating Ovarian Cancer
Cancers · 24.01.2024 · 16 (3) · 500
DOI: 10.3390/cancers16030500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 24.01.2024. Verfasst von Alexia B Collier und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Ovarian cancer (OCa) is the most lethal form of gynecologic cancer, and the tumor heterogeneities at the molecular, cellular, and tissue levels fuel tumor resistance to standard therapies and pose a substantial clinical challenge. Here, we tested the hypothesis that the heightened basal endoplasmic reticulum stress (ERS) observed in OCa represents an exploitable vulnerability and may overcome tumor heterogeneity. Our recent studies identified LIPA as a novel target to induce ERS in cancer cells using the small molecule ERX-41. However, the role of LIPA and theutility of ERX-41 to treat OCa remain unknown. Expression analysis using the TNMplot web tool, TCGA data sets, and immunohistochemistry analysis using a tumor tissue array showed that LIPA is highly expressed in OCa tissues, compared to normal tissues. ERX-41 treatment significantly reduced the cell viability and colony formation ability and promoted the apoptosis of OCa cells. Mechanistic studies revealed a robust and consistent induction of ERS markers, including CHOP, elF2α, PERK, and ATF4, upon ERX-41 treatment. In xenograft and PDX studies, ERX-41 treatment resulted in a significant reduction in tumor growth. Collectively, our results suggest that ERX-41 is a novel therapeutic agent that targets the LIPA with a unique mechanism of ERS induction, which could be exploited to treat heterogeneity in OCa.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
- Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
- Department of Chemistry and Biochemistry, University of Texas at Dallas, Richardson, TX 75080, USA.
- Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
- Greehey Children's Cancer Research Institute, Department of Cell Systems & Anatomy, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
- Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, TX 78229, USA.
ORCID-Profile: Suryavathi Viswanadhapalli, Kara Kassees, Megharani Mahajan, Gangadhara R Sareddy, Jung-Mo Ahn, Ratna K Vadlamudi
Förderung
- NCI NIH HHS
- NIH HHS
- NIGMS NIH HHS
- DOD
- PREP
Zitieren
APA
Collier, A. B., Viswanadhapalli, S., Gopalam, R., Lee, T. K., Kassees, K., Parra, K., Sharma, G., Reese, T. C., Liu, X., Yang, X., Ebrahimi, B., Pratap, U. P., Mahajan, M., Arnold, W. C., Baker, A., Chen, C. Y., Elmore, S. T., Subbarayalu, P., Sareddy, G. R., …, & Vadlamudi, R. K. (2024). Novel LIPA-Targeted Therapy for Treating Ovarian Cancer. Cancers, 16(3), 500. https://doi.org/10.3390/cancers16030500
Vancouver
Collier AB, Viswanadhapalli S, Gopalam R, Lee TK, Kassees K, Parra K, et al. Novel LIPA-Targeted Therapy for Treating Ovarian Cancer. Cancers. 2024;16(3):500. doi:10.3390/cancers16030500
BibTeX
@article{Collier2024,
author = {Collier, Alexia B and Viswanadhapalli, Suryavathi and Gopalam, Rahul and Lee, Tae-Kyung and Kassees, Kara and Parra, Karla and Sharma, Gaurav and Reese, Tanner C and Liu, Xihui and Yang, Xue and Ebrahimi, Behnam and Pratap, Uday P and Mahajan, Megharani and Arnold, William C and Baker, Adriana and Chen, Chia-Yuan and Elmore, Scott Terry and Subbarayalu, Panneerdoss and Sareddy, Gangadhara R and Valente, Philip T and Kost, Edward R and Ahn, Jung-Mo and Vadlamudi, Ratna K},
title = {Novel LIPA-Targeted Therapy for Treating Ovarian Cancer},
journal = {Cancers},
year = {2024},
volume = {16},
number = {3},
pages = {500},
doi = {10.3390/cancers16030500}
}
EUVIMED